Similar articles

• Consortium Outlines 3 Solutions to Maximize the Benefit and Affordability of Targeted Cancer Drugs.

  [No authors listed] [No authors listed] Cancer. 2018 Aug;124(16):3283. doi: 10.1002/cncr.31673. Cancer. 2018. PMID: 30141838 No abstract available.
• Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.

  Amir E, Seruga B, Martinez-Lopez J, Kwong R, Pandiella A, Tannock IF, Ocaña A. Amir E, et al. J Clin Oncol. 2011 Jun 20;29(18):2543-9. doi: 10.1200/JCO.2011.35.2393. Epub 2011 May 23. J Clin Oncol. 2011. PMID: 21606435
• Estimated costs of pivotal trials for U.S. Food and Drug Administration-approved cancer drugs, 2015-2017.

  Hsiue EH, Moore TJ, Alexander GC. Hsiue EH, et al. Clin Trials. 2020 Apr;17(2):119-125. doi: 10.1177/1740774520907609. Epub 2020 Feb 29. Clin Trials. 2020. PMID: 32114790
• Benefit and harms of new anti-cancer drugs.

  Vera-Badillo FE, Al-Mubarak M, Templeton AJ, Amir E. Vera-Badillo FE, et al. Curr Oncol Rep. 2013 Jun;15(3):270-5. doi: 10.1007/s11912-013-0303-y. Curr Oncol Rep. 2013. PMID: 23435854 Review.
• [New cytostatic drugs--indications and costs].

  Schefer H, Lehmann B, Joss R. Schefer H, et al. Praxis (Bern 1994). 1999 Apr 29;88(18):791-801. Praxis (Bern 1994). 1999. PMID: 10409876 Review. German.